Articles from Dr. Vince Clinical Research

Dr. Vince Clinical Research (DVCR), a contract research organization (CRO), announces the expansion of its research campus by constructing a new 5,000-square-foot administration building in Overland Park, Kansas. This project continues its breakthrough expansion for the company as it enhances its clinical research capabilities and services. The organization currently has well over 175 employees across the United States, Canada, Europe and the United Kingdom.

Dr. Vince Clinical Research (DVCR) is pleased to announce the addition of a cutting-edge clinical laboratory within the main building of its research campus. This new laboratory will significantly enhance the capabilities of its clinical pharmacology unit by enabling in-house safety laboratory testing and streamlining operations.

Dr. Vince Clinical Research (DVCR), a full-service contract research organization (CRO), today announced the appointment of Sheldon Preskorn, M.D., as its Senior Vice President of Neuroscience. Dr. Preskorn is a world-renowned researcher, academic physician, psychiatrist, clinical researcher, neuropsychopharmacologist and medical educator. He has worked with over 140 pharmaceutical, biotech, device and diagnostic companies and has worked on 16 successful new drug applications. His publications include over 500 medical papers, books and book chapters, with over 18,000 citations in medical literature. Further, Dr. Preskorn has served as a consultant to the FDA, EMA and NIH and has lectured in 55 countries and at most medical schools in the U.S. and throughout the world.

Dr. Vince Clinical Research (DVCR), a contract research organization (CRO) specializing in early phase trials, announced the first dosing in a Phase II multicenter trial of SPN-820 in adults with major depressive disorder (MDD). DVCR is acting as the full-service CRO for this trial. MDD is estimated to affect over 17 million adults in the United States, with approximately 30% of these patients being resistant to treatment.

Dr. Vince Clinical Research (DVCR), a full-service Phase I-II contract research organization (CRO), announced a new solution to conduct renal and hepatic impairment studies. The solution leverages trusted relationships and more effective management of highly regarded specialty sites and subject matter experts to optimize study timelines, ensure efficient recruitment and generate quality data in this highly competitive space. By combining DVCR’s full suite of clinical trial services with their sites’ expertise and thorough understanding of the patient populations required for these studies, this end-to-end solution will challenge the current landscape for managing organ impairment studies.

Dr. Vince Clinical Research (DVCR), a full-service clinical research organization (CRO), today announced the first dosing in Cingulate Therapeutics’ CTx-1301 Phase III dose-optimization onset and duration laboratory classroom study. This study is taking place in pediatric patients ages 6-12 with attention-deficit/hyperactivity disorder (ADHD) and also marks the launch of DVCR’s multisite clinical trial offering to biopharmaceutical companies.

Dr. Vince Clinical Research (DVCR), an early phase Clinical Research Organization (CRO), today announced a new collaboration with Clario, a leading healthcare research and technology company that delivers leading endpoint technology solutions for clinical trials.

Dr. Vince Clinical Research (DVCR), a full-service CRO specializing in Phase I-II clinical trials, announced today the first subject was screened for Cessation Therapeutics’ CSX-1004 in a First-In-Human single ascending dose study in normal healthy volunteers. CSX-1004 is a human monoclonal antibody infusion that is being developed for the prevention of fentanyl overdose. The study is being conducted at DVCR’s world-class clinical pharmacology unit located in Overland Park, Kansas.

Dr. Vince Clinical Research, a full-service Phase I-II contract research organization (CRO), announced its world-class clinical pharmacology unit, which opened in September, was awarded two Green Globes certifications.

Dr. Vince Clinical Research (DVCR), an early phase CRO specializing in Phase I trials, announced that it has administered the first dose of Aclaris Therapeutics’ ATI-2138 in a Phase I multiple ascending dose (MAD) study for an investigational oral compound being developed for the treatment of autoimmune diseases. The Phase I MAD study in healthy volunteers is being conducted at DVCR’s world-class clinical pharmacology unit.

Overland Park, KS., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Dr. Vince Clinical Research (DVCR) announced the addition of highly experienced investigator George J. Atiee, M.D. to the medical team at its world-class clinical pharmacology unit.

Overland Park, KS., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Dr. Vince Clinical Research (DVCR), a world-class early phase contract research organization (CRO) specializing in the conduct of Phase I clinical trials, today announced that it has administered the first dose in Ensysce Bioscience’s oral Human Abuse Potential (HAP) study in recreational drug users.

Dr. Vince Clinical Research (DVCR), today announced the launch of its new, world-class clinical pharmacology unit and headquarters in Overland Park, Kansas. The custom-built, green-inspired research complex was intentionally designed and engineered — with significant investments in infrastructure, research-changing technologies, employee wellness and excellence and environmental sustainability — to be the premier destination in the country for Phase I clinical studies.

WCG, the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the expansion of its Phase I review services, providing purpose-built operations for Phase I investigators. Launched in conjunction with the opening of Dr. Vince Clinical Research’s (DVCR) industry-leading, green-designed research complex in Overland Park, Kansas — who selected WCG as their institutional review board (IRB) of record — these expanded services will provide faster timelines in the clinical trial process without sacrificing superior levels of human subject protection for early stage and clinical pharmacology research.

Dr. Vince Clinical Research (DVCR), a world-class contract research organization (CRO) specializing in early phase clinical trials, today announced the addition of two key leadership roles to its Phase I research team.